Condition (MeSH)
Zoonoses
ClinicalTrials.gov lists 12 trials for Zoonoses or a narrower condition beneath it. Institut Pasteur has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Zoonoses itself; the rest are tagged with a narrower condition beneath it.
When did Zoonoses trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 3 |
| 2019 | 2 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Zoonoses trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Not applicable | 1 |
| Observational | 9 |
How many Zoonoses trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 3 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Zoonoses trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Institut Pasteur | 2 |
| OpenGenome | 1 |
| Public Health Vaccines LLC | 1 |
| Synermore Biologics (Suzhou) Co., Ltd. | 1 |
Which drugs are being tested for Zoonoses? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Rabies Vaccine | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| BLOOD SAMPLES | 1 |
| Stool collection | 1 |
| PHV02 | 1 |
| Blood Sampling | 1 |
| recombinant anti-rabies human monoclonal antibody injection (SYN023) | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Zoonoses? (111)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Tracing the future of epidemics: Coincident niche distribution of host animals and disease incidence revealed climate-correlated risk shifts of main zoonotic diseases in China. | Global change biology | 2023 | Yes |
| Effectiveness of doxycycline for the treatment of zoonotic cutaneous leishmaniasis <i>in vivo</i>. | Parasitology | 2021 | Yes |
| Structural basis of receptor recognition by SARS-CoV-2. | Nature | 2020 | Yes |
| The proximal origin of SARS-CoV-2. | Nature medicine | 2020 | Yes |
| Middle East Respiratory Syndrome Coronavirus Transmission. | Emerging infectious diseases | 2020 | Yes |
Showing 5 of 111 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.